Three cases of immune cholangitis related to anti–programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer

Anti-programmed cell death (anti-PD1) and anti-programmed cell death ligand (anti-PDL1) agents are immunotherapy with a growing number of indications. The safety profile is different from chemotherapy resulting of the abnormal activation of the immune system. Most of immune-related adverse events become common, but some, infrequent, are not very well-known. Here, we report the observation of three patients followed in our oncology department for...